image

The best stocks to buy since 1993

Latest issue now available

SIGN UP NOW
Updates

Tristel - Tristel OPH approval expected by year end

April 2024

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • TSTL
  • Price:
  • 447.5p
Tristel has reported its H1, albeit the period included relatively little of the royalty income from Parker Laboratories, which is manufacturing and distributing Tristel ULT for high-end disinfection of ultrasound probes in North America. As finance director Liz Dixon explains, it was only once the FDA had approved ULT that labelling could be finalised and Parker undertook the first production run in October. Consequently, there was only 10 weeks of actual sales activity, which generated a 24% royalty.  As it was, H1 sales were +20% to £20.9m driven by volume (c.8%) and price increases (12%) but only included £46k royalty. Medical device sales of ULT in France, Germany and the UK were +25% to £18.3m, growing in line with more diag ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Tristel (August 2024)
Tristel - Sets its sights on the US market (November 2023)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author

LIMITED PERIOD OFFER

SUBSCRIBE TODAY AND SAVE £40 WITH OFFER CODE 40OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe

SUBSCRIBE NOW